Strategic partnership to drive growth of precision medicine ecosystem

The Precision Medicine Catapult, the UK’s innovation centre for precision medicine, has entered into a strategic partnership with the UK Pharmacogenetics and Stratified Medicine Network.

The two organisations will work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes.

The Network was founded in 2010 by Professor Sir Munir Pirmohamed, NHS Chair of Pharmacogenetics at the University of Liverpool, following a Department of Health Genetics White Paper. Providing an essential link between academics, clinicians and others, its aim is to accelerate delivery of precision medicine to patients. There are over 400 individual members drawn from academia, medicine, industry, regulatory authorities and patient groups across the UK and elsewhere, the majority of whom are engaged in research into patient and/or disease stratification.

The Precision Medicine Catapult, created in April 2015 by Innovate UK, brings access to unique programmes, collaborations, initiatives and expertise from its global connections. Previously funded by the Department of Health and the Knowledge Transfer Network, the UK Pharmacogenetics and Stratified Medicine Network will now be supported by the Precision Medicine Catapult in its next stage of growth, and together the partners will drive the growth of the UK industry.

John McKinley, CEO of the Precision Medicine Catapult, said: “The UK Pharmacogenetics and Stratified Medicine Network has connected many of the leading stakeholders in the precision medicine landscape, so it makes perfect sense for our two organisations to partner and deliver engagement.”

Professor Sir Munir Pirmohamed, NHS Chair of Pharmacogenetics at the University of Liverpool, and founder of the UK Pharmacogenetics and Stratified Medicine Network, added: “With the Precision Medicine Catapult’s commitment to making precision medicine a reality in the UK, this partnership significantly increases the impact of our network’s activities. We expect this collaboration to be highly effective as we work together to develop the precision medicine solutions which are revolutionising healthcare.”


A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Related news

In brief: New head of R&D for Cellbox Solutions

Germany’s Cellbox Solutions has appointed Lonza Pharma and Biotech’s former Head of Biosolutions R&D as its new Head of R&D. Dr Herbert A. Mueller-Hartmann will...

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...